Compare RVSB & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | CGTX |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 110.8M |
| IPO Year | 1997 | 2021 |
| Metric | RVSB | CGTX |
|---|---|---|
| Price | $5.45 | $1.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.00 | $3.33 |
| AVG Volume (30 Days) | 30.8K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $0.22 |
| 52 Week High | $6.31 | $3.83 |
| Indicator | RVSB | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 50.31 |
| Support Level | $4.90 | $1.01 |
| Resistance Level | $5.57 | $1.19 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 73.17 | 13.04 |
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).